ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN MATCHED SIBLINGS

匹配兄弟姐妹的同种异体外周血干细胞移植

• 批准号: 6300135
• 负责人: FREDERICK APPELBAUM
• 金额: $ 34.64万
• 依托单位: FRED HUTCHINSON CANCER RESEARCH CENTER
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-01-26 至 2000-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6300135
• 关键词: CD4 molecule; CD8 molecule; bone marrow transplantation; chronic myelogenous leukemia; clinical research; clinical trials; combination therapy; graft versus host disease; hematopoietic stem cells; histocompatibility typing; homologous transplantation; human subject; human therapy evaluation; leukemia; medical complication; neoplasm /cancer immunotherapy; siblings

The overall objective of this Project is to determine if the outcome of allogeneic transplantation for hematologic malignancies can be improved through the use of growth factor mobilized peripheral blood stem cells (PSBCs) instead of marrow. Initially, a prospective randomized trail will be performed in patients with a variety of hematologic malignancies undergoing transplantation from matched siblings in which the outcome using unmodified G-CSF mobilized PBSCs will be compared with that using marrow. If the results demonstrate that PBSCs lead to more rapid engraftment without a significant increase in graft-versus-host disease (GVHD), the trail will be continued in patients with a single hematologic malignancy, chronic myeloid leukemia. Additional studies will be carried out examining if the results of transplantation using PBSCs can be further improved by partial T cell depletion. Specifically, clinical studies will be conducted based on animal experiments demonstrating that engraftment without GVHD can be achieved with complete CD4 and partial CD8 depletion. The results of these studies should define the optimal stem cell product for use in matched sibling transplantation.

本项目的总体目标是确定 用于恶性血液病的同种异体移植可以 通过使用生长因子动员的外周血改善 干细胞（PSBC），而不是骨髓。 一开始，一个准 随机试验将在患有各种 接受来自匹配的移植的恶性血液病 使用未修饰的G-CSF动员的PBSC的结果 将与骨髓移植进行比较。 如果结果显示 PBSC导致更快的植入， 增加移植物抗宿主病（GVHD），试验将 在患有单一恶性血液病、慢性 粒细胞白血病 将进行更多的研究， 使用PBSC的移植结果可以进一步改善， 通过部分T细胞耗竭。 具体而言，临床研究将 基于动物实验进行，证明植入 没有GVHD可以实现完全CD 4和部分CD 8 耗尽 这些研究的结果应确定最佳股骨柄 用于匹配的同胞移植的细胞产品。